Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Update

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 289,400 shares, a decline of 18.0% from the February 13th total of 353,000 shares. Currently, 1.3% of the company’s shares are sold short. Based on an average trading volume of 263,000 shares, the short-interest ratio is currently 1.1 days.

Eton Pharmaceuticals Stock Performance

Shares of NASDAQ ETON opened at $14.88 on Thursday. The stock has a 50 day moving average price of $15.51 and a 200 day moving average price of $11.45. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $18.41. The stock has a market capitalization of $387.64 million, a PE ratio of -67.64 and a beta of 1.37.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). The firm had revenue of $11.65 million during the quarter, compared to analysts’ expectations of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, research analysts forecast that Eton Pharmaceuticals will post -0.14 EPS for the current year.

Institutional Trading of Eton Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eton Pharmaceuticals in the third quarter valued at approximately $54,000. Tower Research Capital LLC TRC bought a new stake in Eton Pharmaceuticals in the fourth quarter valued at approximately $86,000. Jane Street Group LLC bought a new stake in Eton Pharmaceuticals in the third quarter valued at approximately $90,000. Jefferies Financial Group Inc. bought a new stake in Eton Pharmaceuticals in the fourth quarter valued at approximately $133,000. Finally, Raymond James Financial Inc. bought a new stake in Eton Pharmaceuticals in the fourth quarter valued at approximately $147,000. Institutional investors own 27.86% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ETON. B. Riley reaffirmed a “buy” rating and set a $24.00 price objective (up from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday. Craig Hallum upped their price objective on Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a research report on Wednesday.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.